Drug development rarely happens in isolation. Bringing a promising therapeutic from early research toward the clinic requires specialized expertise, thoughtful planning and the ability to translate complex data from multiple sources into decisions that move a technology forward. That thinking is behind a new consulting collaboration between Lovelace Biomedical and Matt Reed, PhD, an independent pharmacology and board-certified toxicology consultant ... Read More The post A Collaborative Approach to Respiratory Drug Development: A Q&A with Matt Reed, PhD, DABT, F-ATS appeared first on Lovelace Biomedical .